About this trial
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Patient Profile
Patients with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Where’s this trial being run?
Beaumont Hospital, Bon Secours Cork, Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | lidERA Breast Cancer/ GO42784/ TRIO 045 |
|---|---|
| Number: | 21-04 |
| Full Title: | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer |
| Principal Investigator: | Prof Janice Walshe (St. Vincent’s University Hospital) |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Hoffmann-La Roche |
| Recruitment Started: |
Global: Aug 2021 Ireland: Oct 2021 |
| Global Recruitment Target: | 4100 |
|---|---|
| Ireland Recruitment Target: | 40 |